bioRxiv Science⌕ Search

Biology subjects

Nakatsukasa, K.

Publications and source records attributed to Nakatsukasa, K..

2 recordsLinked to original sources

ER-associated degradation by Doa10 restrains mitophagy in yeast

Degradation of defective or superfluous mitochondria via mitophagy, a specialized form of selective autophagy, is important for maintaining mitochondrial quality and quantity. In yeast, the pro-mitophagic factor Atg32 is transcriptionally upregulated upon oxidative stress and anchored to the mitochondrial surface, where it acts as a molecular signal to initiate efficient degradation of mitochondria. However, how the protein levels of Atg32 are regulated post-translationally remains enigmatic. Here we show that the endoplasmic reticulum (ER) serves as a hub to govern Atg32 protein turnover. We found that the ER-associated degradation (ERAD) E3 ligase Doa10 interacts with Atg32, leading to its degradation by the proteasome. Furthermore, we show that Atg32 is destined for the ER in a manner dependent on the GET (guided entry of tail-anchored proteins) pathway, which mediates the delivery of tail-anchored (TA) proteins to the ER where Atg32 is potentially recognized by Doa10. Notably, Doa10 deficiency increased Atg32 levels and enhanced mitophagy under respiratory conditions, thus determining that ERAD serves as a brake on mitophagy.

cell biology↗

Hydroxyurea inhibits ERAD-L independently of S-phase arrest in budding yeast

Misfolded luminal and membrane proteins in the endoplasmic reticulum (ER) are recognized and retrotranslocated to the cytosol for proteasomal degradation, a process referred to as ER-associated degradation (ERAD). In Saccharomyces cerevisiae, ERAD substrates with luminal lesions are targeted for proteasomal degradation by the Hrd1 ubiquitin ligase complex (ERAD-L pathway). Membrane proteins containing lesions within their membrane-spanning regions are also targeted for degradation by the Hrd1 complex (ERAD-M pathway), while those containing lesions within their cytosolic regions are targeted for degradation mainly by the Doa10 ubiquitin ligase complex (ERAD-C pathway). Here, we demonstrate that hydroxyurea (HU), which is widely used to arrest cells in S-phase and is also used to manage several diseases including sickle cell anemia and chronic myeloproliferative disorders, inhibited ERAD-L, but not ERAD-M or -C. HU-mediated inhibition of ERAD-L occurred independently of S-phase arrest. In HU-treated cells, the integrity of the Hrd1 ubiquitin ligase complex remained intact and substrate recognition was unaffected. Moreover, induction of the unfolded protein response was undetectable in cells in which ERAD-L was inhibited by HU. These results suggest an unexpected action of HU, which modulates protein quality control in the secretory pathway, and also suggest the existence of an additional regulatory step in ERAD.

biochemistry↗